Why Nurtec™ ODT (rimegepant)
Based on patient-reported insights:
For people suffering from migraine, living with trade-offs is a painful reality1,2
For the busy professional, it can mean choosing between: Treating their migraine and missing a workday, AGAIN1 OR Holding off treatment and having an unproductive day at the office, AGAIN1
For the mom on-the-go, it can mean choosing between: Treating their migraine and missing out on family time because of dizziness and tiredness2 OR Holding off treatment and having the pain of migraine as an unbearable distraction2
For the active multitasker, it can mean choosing between: Treating their migraine and feeling wiped out2 OR Holding off treatment and fighting through every minute due to concerns about treatment side effects2
74% of patients were not completely satisfied with their acute treatments.3
of people reported that the side effects of their migraine treatments interfered with their ability to work or go to school.4
Based on a December 23, 2019-January 17, 2020 U.S. online survey completed by 528 adults with migraine. Respondents were recruited from the National Headache Foundation membership list.3
One dose can inhibit three CGRP*-induced effects by selectively binding to CGRP receptors 5-9
*Calcitonin gene-related peptide
References: 1. Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK. A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns. Headache. 2017;57(10):1532-1544. doi: 10.1111/head.13202. 2. Data on File. RIM127. Biohaven Pharmaceuticals Inc. 3. Data on File. RIM144. Biohaven Pharmaceuticals Inc. 4. Data on File. RIM145. Biohaven Pharmaceuticals Inc. 5. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 6. Durham PL. CGRP-Receptor Antagonists — A Fresh Approach to Migraine Therapy? N Engl J Med. 2004;350(11):1073-1075. doi: 10.1056/NEJMp048016. 7. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622. doi: 10.1152/physrev.00034.2015. 8. Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache. 2019;59(5):659-681. doi: 10.1111/head.13529. 9. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338-350. doi: 10.1038/s41582-018-0003-1.
Contraindications: Hypersensitivity to Nurtec ODT or any of its components.
Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.
Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.
Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P‑gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.
Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.
Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use
Nurtec ODT is not indicated for the preventive treatment of migraine.
Please click here for full Prescribing Information.